Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAG regimen vs low dose cytarabine in elderly AML
NCT02432911Unknown
- Start
- Apr 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of aclarubicin in acute myeloid leukemia (AML). Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
aclarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02432911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432911.